Monopar Therapeutics Reports Q2 2026 Financial Results

What Happened
Monopar Therapeutics (MNPR) filed a Form 8‑K on August 12, 2026 under Item 2.02 to announce its results of operations and financial condition. The company issued a press release with its financial results for the second quarter ended June 30, 2026; that press release is included as Exhibit 99.1 to the filing.

Key Details

• Filing date: August 12, 2026 (Form 8‑K, Item 2.02).
• Reporting period: Quarter ended June 30, 2026.
• The company’s press release with the detailed quarterly results is attached as Exhibit 99.1.
• The 8‑K does not replace formal periodic reports (e.g., upcoming 10‑Q) that contain audited/complete financial statements.

Why It Matters
This filing provides Monopar’s latest quarterly earnings and financial-condition update — the primary public source for revenue, expenses, cash position and management commentary for Q2 2026. Retail investors should review the attached press release (Exhibit 99.1) for the specific figures and any guidance or operational updates, and watch for the company’s subsequent periodic filings (10‑Q) for full financial statements and disclosures.